Yttrium (90Y) clivatuzumab tetraxetan
|Source||Humanized (from mouse)|
|Chemical and physical data|
|Molar mass||145,723.71 g·mol−1|
|(what is this?)|
Yttrium (90Y) clivatuzumab tetraxetan (trade name hPAM4-Cide) is a humanized monoclonal antibody-drug conjugate designed for the treatment of pancreatic cancer. The antibody part, clivatuzumab (targeted at MUC1), is conjugated with tetraxetan, a chelator for yttrium-90, a radioisotope which destroys the tumour cells.
The drug was developed by Immunomedics, Inc.
In March 2016 the phase III PANCRIT-1 trial in metastatic pancreatic cancer was terminated early due to lack of improvement of overall survival.
- "Statement On A Nonproprietary Name Adopted By The USAN Council: Yttrium Y90 clivatuzumab tetraxetan" (PDF). American Medical Association.
- WHO Drug Information
- Immunomedics Provides Update on Phase 3 PANCRIT-1 Trial of Clivatuzumab Tetraxetan in Patients With Advanced Pancreatic Cancer. March 2016
|This monoclonal antibody-related article is a stub. You can help Wikipedia by expanding it.|
|This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.|